Voya Investment Management LLC Sells 13,515 Shares of Hologic, Inc. $HOLX

Voya Investment Management LLC cut its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 125,376 shares of the medical equipment provider’s stock after selling 13,515 shares during the quarter. Voya Investment Management LLC owned approximately 0.06% of Hologic worth $7,744,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of HOLX. Beverly Hills Private Wealth LLC boosted its position in Hologic by 3.6% in the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock worth $320,000 after purchasing an additional 180 shares during the last quarter. Allworth Financial LP raised its stake in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares during the period. Integrated Advisors Network LLC raised its stake in shares of Hologic by 5.4% during the 1st quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider’s stock worth $346,000 after purchasing an additional 289 shares during the period. Townsquare Capital LLC boosted its holdings in shares of Hologic by 4.5% in the 1st quarter. Townsquare Capital LLC now owns 6,763 shares of the medical equipment provider’s stock worth $418,000 after buying an additional 293 shares during the last quarter. Finally, Empirical Finance LLC grew its position in Hologic by 4.0% during the first quarter. Empirical Finance LLC now owns 8,703 shares of the medical equipment provider’s stock valued at $538,000 after buying an additional 334 shares during the period. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on HOLX shares. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Argus raised Hologic from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Monday, August 18th. Evercore ISI increased their price target on Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 8th. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Hologic Stock Up 7.7%

HOLX opened at $68.20 on Thursday. The company has a fifty day moving average price of $66.43 and a 200-day moving average price of $62.69. The firm has a market capitalization of $15.17 billion, a P/E ratio of 28.30, a price-to-earnings-growth ratio of 2.30 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the company earned $1.06 earnings per share. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.